Press Releases

Month Year

Month Year

Feb 9, 2021

FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma

Following Priority Review Libtayo receives full approval in locally advanced basal cell carcinoma (BCC) and accelerated approval in metastatic BCC
Feb 5, 2021

Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021
Feb 2, 2021

Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease
Feb 1, 2021

New Dupixent® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting

-- Improvements were noted across key disease measures in certain patients with asthma, atopic dermatitis, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis
Dec 10, 2020

Sanofi to resume dosing in fitusiran clinical studies in the U.S.

Show per page

Print
Email page
RSS